𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients

✍ Scribed by Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara

Publisher
Springer
Year
2011
Tongue
English
Weight
365 KB
Volume
15
Category
Article
ISSN
1342-1751

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of low-dose valganci
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d

Pharmacokinetics, efficacy, and safety o
Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients
✍ BjΓΆrn Nashan; Faouzi Saliba; Francois Durand; Rafael BarcΓ©na; Jose Ignacio Herre πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 455 KB πŸ‘ 1 views

The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepati